SCHEMBL2184425

SCHEMBL2184425

N#Cc1ccc(-c2cccc3c2c2ccccc2n3-c2ccc(C(=O)O)c(N[C@H]3CC[C@H](O)CC3)c2)cn1

nearest known ligand 0.47

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 19/20 0.47
USP14 P54578 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3417339 1.00 HSP90AA1 (0.47) HSP90AA1USP14
SCHEMBL2182811 0.93 HSP90AA1 (0.55) HSP90AA1
SCHEMBL2182322 0.92 HSP90AA1 (0.41) HSP90AA1USP14
SCHEMBL2183606 0.89 HSP90AA1 (0.45) HSP90AA1USP14
SCHEMBL2183601 0.89 HSP90AA1 (0.45) HSP90AA1USP14
SCHEMBL2182669 0.88 CHEK1 (0.43) HSP90AA1USP14
Hydrochloric Acid SCHEMBL2184372 0.87 CHEK1 (0.43) HSP90AA1USP14
SCHEMBL2185932 0.86 HSP90AA1 (0.36) HSP90AA1USP14
SCHEMBL2184516 0.85 HSP90AA1 (0.48) HSP90AA1
SCHEMBL3415025 0.82 AXL (0.41) USP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309721-B2 HSP90 inhibitory carbazole derivatives, compositions containing same and use thereof SANOFI (FR) 2012-11-13 US disclosed
US-20110166169-A1 NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF SANOFI-AVENTIS (FR) 2011-07-07 US disclosed
EP-2265598-A2 NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, AND USE THEREOF Sanofi-Aventis (FR) 2010-12-29 EP disclosed
WO-2009122034-A2 NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, AND USE THEREOF SANOFI-AVENTIS (FR) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166169-A1 NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF HSP90AB2P, HSP90AB1, HSP90AA1 HSP90AA1 3/4885USP14 2783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.